Litronesib

Drug Profile

Litronesib

Alternative Names: KF 89617; LY 2523355

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer Eli Lilly; Kyowa Hakko
  • Class Amides; Antineoplastics; Small molecules; Thiadiazoles
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Leukaemia; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 26 Apr 2013 Discontinued - Phase-I for Leukaemia (acute leukaemia) in USA (IV)
  • 26 Apr 2013 Discontinued - Phase-I for Solid tumours (late-stage disease, metastatic disease) in Japan (IV)
  • 26 Apr 2013 Discontinued - Phase-II for Breast cancer (metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top